What CoVita does

CoVita (coVita, LLC) is a privately held medical device company founded in 1976 and headquartered in The Woodlands, Texas, specializing in breath analysis instrumentation for clinical, occupational health, and consumer applications. Operating through its US entity and its UK sister company Bedfont Scientific in Harrietsham, Kent, the company manufactures electrochemical and infrared sensor-based monitors that quantify carbon monoxide (Smokerlyzer, ToxCO, iCOquit), fractional exhaled nitric oxide for asthma management (NObreath), and hydrogen/methane for gastrointestinal disorders (Gastrolyzer, GastroCHECK). With 101-250 employees and over 3 million devices deployed globally across more than 45 years, the company serves hospitals, respiratory and allergy clinics, fire and EMS departments, smoking cessation programs, substance abuse treatment facilities, major research institutions, and increasingly direct-to-consumer health-conscious individuals.

The company sells hardware at price points ranging from $69.99 (consumer iCOquit) to $15,995 (GastroCHECK clinical analyzer), generating recurring revenue through proprietary consumables including mouthpieces, calibration gases, and SteriBreath accessories, supplemented by companion iOS and Android apps for data capture and longitudinal tracking. Its products hold FDA clearances across multiple categories and align with ATS clinical guidelines for FeNO measurement, enabling providers to bill under established CPT reimbursement codes including 95012 (nitric oxide expired gas), 99406/99407 (smoking cessation counseling), and 91065 (breath hydrogen test). CoVita's commercial model combines direct sales to enterprise and clinical accounts with channel partnerships, notably its November 2025 partnership with Allergy Partners covering 110+ clinics across 20 states.

The business operates on a capital-efficient, profitable basis with no disclosed outside funding, reflecting 45+ years of operating history and mature unit economics reported as low as $0.15 per test. CoVita has historically expanded its portfolio from smoking cessation (Smokerlyzer, 1980s) into gastrointestinal diagnostics (Gastrolyzer, 2000s), asthma management (NObreath, 2010s), toxicology (ToxCO), and most recently consumer health (iCOquit with Bluetooth connectivity), positioning the company across the full spectrum of breath-based diagnostic and monitoring use cases.

Name

CoVita

Legal name

coVita, LLC

Website

https://covita.net

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

101–250 employees

Short description

CoVita is a 1976-founded medical device company that designs, manufactures, and sells FDA-cleared breath analyzers for carbon monoxide, FeNO asthma, and gastrointestinal diagnostics, serving hospitals, clinics, research institutions, fire departments, and consumers via its US and UK operations.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices – Breath Analysis

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

akta.pro secondary industries

Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD), Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC), Pulse Oximeters & Respiratory Monitors (Consumer) (CRACAQAF)

Keywords

• Breath analysis devices
• Medical diagnostic monitors
• Smoking cessation equipment
• FeNO asthma testing
• CO poisoning detection

Headquarters

HQ city

The Woodlands

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Breath Analysis Hardware Sales: CoVita generates revenue primarily through the sale of medical diagnostic breath analysis monitors and accessories. Products include professional-grade monitors (Smokerlyzer, ToxCO, NObreath, Gastrolyzer) sold to healthcare providers, institutions, and organizations, as well as consumer-grade devices like the iCOquit personal monitor. The company also sells consumables, calibration gases, and accessories.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

CoVita develops, manufactures, and sells FDA-cleared medical breath analysis monitors used by healthcare professionals and institutions to measure carbon monoxide (CO), fractional exhaled nitric oxide (FeNO), hydrogen (H2), and methane (CH4) for clinical applications including smoking cessation programs, asthma management, carbon monoxide poisoning detection, and gastrointestinal disorder diagnosis. The portfolio spans professional-grade clinical monitors (Smokerlyzer, NObreath, ToxCO, Gastrolyzer ranges) along with a consumer smartphone-connected device (iCOquit) and proprietary companion software for patient data management. Accessories, calibration gases, consumables, and infection-control mouthpieces are sold alongside the monitors.

Product overview

CoVita offers a portfolio of medical diagnostic breath analysis devices organized into four product families: Smokerlyzer® (carbon monoxide monitors for smoking cessation), NObreath® (FeNO monitors for asthma management), ToxCO® (CO poisoning monitors), and Gastrolyzer® (hydrogen and methane monitors for GI disorders). The company also provides proprietary companion software including FeNOchart™, COdata+™, GastroCHART™, and ToxCOData™ for data management and patient tracking. Accessories include calibration gases, mouthpieces, D-pieces, and test kits. Products range from professional clinical-grade monitors to consumer smartphone-connected devices, with pricing from approximately $70 (iCOquit) to over $15,000 (GastroCHECK).

Differentiator

Problem solved

Functional benefit

Brands

• Smokerlyzer: Breath carbon monoxide (CO) monitors for smoking cessation, tobacco treatment, and clinical research
• ToxCO
• NObreath
• Gastrolyzer
• iCOquit

Products and services

• Micro+ pro Smokerlyzer Professional-grade breath CO monitor with automatic on-device biofeedback displaying PPM (CO in lungs), %COHb (CO in blood), %FetalCOHb (fetus CO level), and ambient air monitoring. Features a color touchscreen, instant boot-up, and a 5-year warranty. Priced $1,190.00 – $1,400.65.
• Micro+ baby Smokerlyzer CO monitor designed for prenatal and postpartum tobacco treatment programs with automatic on-device biofeedback, including fetal CO readings. Features a color touchscreen and a 5-year warranty. Priced $650.00 – $872.80.
• Micro+ basic Smokerlyzer Entry-level professional CO monitor with on-device biofeedback and traffic-light display system, color touchscreen, and 5-year warranty. Priced $620.00 – $845.80.
• iCOquit Smokerlyzer (Personal Bluetooth CO Monitor) Pocket-sized personal Bluetooth breath CO monitor for smartphone/tablet use, paired with the free iCOquit app on iOS and Android. Allows users to track quit progress with instant results, share findings, and keep motivated at $69.99 with a 6-month warranty.
• NObreath FeNO Monitor FDA-cleared FeNO (fractional exhaled nitric oxide) monitor for measuring airway inflammation in asthma diagnosis and management. Non-invasive breath test with adult and child modes, unlimited testing capability (validated for up to 29,000 tests), and 5-year warranty on device and sensor. Priced $2,800.00 – $2,973.50.
• ToxCO Monitor FDA-cleared breath CO monitor for determining carbon monoxide poisoning. Features three sampling modes—mouthpiece sampling, face mask sampling for unconscious patients, and ambient monitoring. Auto-saves the last 1,000 readings with time/date stamp. Priced $1,995.00 – $2,435.45 with a 2-year warranty.
• GastroCHECK Gastrolyzer Advanced CH4 and H2 breath monitor with instant warm-up and two sampling modes—mouthpiece sampling and take-home test kits. Includes sample correction, built-in testing protocols, and 2-year warranty. Priced $15,995.00.
• Gastro+ Gastrolyzer Handheld H2-only breath monitor with the ability to manage multiple studies on the device. Features automatic multiple patient testing, built-in protocols, and a 2-year warranty. Priced $2,490.00 – $2,740.40.
• SmokerCOnfirm (Oral Fluid Cotinine Test Kit) Oral fluid cotinine test kits for confirming tobacco use including e-cigarettes/vaping, smokeless tobacco, and conventional cigarette smoking. Provides accurate results in 10 minutes as an add-on to Smokerlyzer devices.

Quantifiable outcome

• Low operating cost: approximately $0.15 per breath test
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Allergy PartnerscoreChannel Partner/ Reseller/ Distributor · 19 November 2025CoVita and Allergy Partners collaborated to provide the NObreath FeNO device in the United States to improve asthma diagnosis and management. This expansion allows Allergy Partners' over 110 clinics across 20 states to utilize non-invasive airway inflammation testing for improved patient outcomes.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• ResMed: Major respiratory/sleep and connected-health platform player (acquired Propeller Health). Comparable in end-user physician base but operates at much broader scale with software-adjacent recurring revenue.
• Vitalograph: Long-established pulmonary diagnostics manufacturer (spirometers, COPD/asthma monitors). Overlaps with CoVita in respiratory physician channels but offers a broader respiratory portfolio rather than breath analysis specialty.
• Philips Respironics: Global respiratory and sleep therapy incumbent with deep pulmonology relationships. Indirect competitor through bundled respiratory diagnostic solutions that could displace specialty breath-analysis vendors.
• COSMED: Manufactures pulmonary function testing equipment and metabolic carts. Competes with NObreath indirectly via broader respiratory diagnostics in hospital and specialty clinic channels.

Emerging players

• Owlstone Medical: Develops breath-based diagnostics (Breath Biopsy) using FAIMS technology for non-invasive disease detection. Adjacent competitor that could expand into CoVita's FeNO and GI breath-testing categories.

Direct peers

• Bedfont Scientific: The UK parent/originator of the breath-analysis technology platform (Harrietsham HQ); CoVita is the US commercial arm of the same underlying R&D and product family. Directly comparable in product, technology, and customer base.
• Bosch Healthcare Solutions (Vivatmo): Sells the Vivatmo me FeNO monitor for clinical and home use. Competes head-to-head with NObreath in the FeNO category, leveraging Bosch's broader sensor and consumer-health distribution.
• NIOX Group: Markets the NIOX VERO and NIOX MINO FeNO monitors for asthma diagnosis and management — the most direct global competitor to CoVita's NObreath in the same physician specialty channel.
• Quintron Instrument Company: Manufactures breath-test analyzers (e.g., BreathTracker) for hydrogen and methane detection of SIBO and carbohydrate malabsorption. Direct competitor to the Gastrolyzer product line.
• CAIRE Diagnostics (formerly Spirosure): Markets Fenom Pro, a FeNO point-of-care monitor for asthma. Direct specialist-channel competitor in the same pulmonology/allergy use cases as NObreath.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCSst5R_UJm1vBf8WSsKqDOQ
• Facebookfacebook.com/covitallc
• LinkedInlinkedin.com/company/covita-llc
• Instagraminstagram.com/covitallc
• Xx.com/covita_llc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoVita